Latanoprost in eyes with uveitic glaucoma

Article

Efficacy and safety of latanoprost in eyes with uveitic glaucoma

Efficacy and safety of latanoprost in eyes with uveitic glaucoma, from Graefe's Archive for Clinical and Experimental Ophthalmology.

Please click here to read the article.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
A cell being injected by a syringe. Image credit: ©Corona Borealis – stock.adobe.com

Trinity team’s gene therapy offers promising glaucoma and AMD treatment

Martin David Harp
September 9th 2024
Article

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A doctor uses the iCare ST500 with a patient. Image courtesy of iCare.

iCare debuts slit-lamp-mounted ST500 tonometer

Hattie Hayes
September 9th 2024
Article

The Finnish company shared technical specifications for the ST500

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A magnet sits in a pile of iron filings. Image credit: ©New Africa – stock.adobe.com

Magnetic cell therapy for corneal endothelial dysfunction

By Lynda Charters; Reviewed by Sumit Garg, MD, ABO
September 6th 2024
Article

Phase 1 multicentre study data demonstrate early signs of efficacy

Miniature figures with backpacks stand on a map of Europe. Image credit: ©kirill_makarov – stock.adobe.com

Unite and conquer: Refractive surgery goes on a world tour

Hattie Hayes
September 4th 2024
Article

The ESCRS Moving Simulator initiative brings surgical training to nations in need

© 2024 MJH Life Sciences

All rights reserved.